|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2009-4-1
|
|
pubmed:abstractText |
AVE5026 is a new hemisynthetic ultra-low-molecular-weight heparin, with a novel anti-thrombotic profile resulting from high anti-factor (F)Xa activity and residual anti-FIIa activity. AVE5026 is in clinical development for venous thromboembolism (VTE) prevention, a frequent complication after total knee replacement (TKR) surgery.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1538-7836
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
7
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
566-72
|
|
pubmed:meshHeading |
pubmed-meshheading:19187076-Adult,
pubmed-meshheading:19187076-Aged,
pubmed-meshheading:19187076-Aged, 80 and over,
pubmed-meshheading:19187076-Arthroplasty, Replacement, Knee,
pubmed-meshheading:19187076-Dose-Response Relationship, Drug,
pubmed-meshheading:19187076-Double-Blind Method,
pubmed-meshheading:19187076-Female,
pubmed-meshheading:19187076-Hemorrhage,
pubmed-meshheading:19187076-Heparin,
pubmed-meshheading:19187076-Heparin, Low-Molecular-Weight,
pubmed-meshheading:19187076-Humans,
pubmed-meshheading:19187076-Male,
pubmed-meshheading:19187076-Middle Aged,
pubmed-meshheading:19187076-Postoperative Complications,
pubmed-meshheading:19187076-Premedication,
pubmed-meshheading:19187076-Risk Assessment,
pubmed-meshheading:19187076-Venous Thromboembolism
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery--TREK: a dose-ranging study.
|
|
pubmed:affiliation |
Hørsholm Hospital, Spine Clinic, Hørsholm, Denmark. mirula@noh.regionh.dk
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial
|
